Does Cosentyx Cause Headaches?
Yes, headaches are a reported side effect of Cosentyx (secukinumab), an IL-17 inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. In clinical trials, headaches occurred in up to 12% of patients, more commonly than in placebo groups (around 8-10%).[1][2]
How Common Are Headaches on Cosentyx?
Headaches rank among the most frequent adverse reactions, affecting 10-15% of users across studies for plaque psoriasis and arthritis. They are typically mild to moderate and often resolve without stopping treatment. Upper respiratory infections and diarrhea are more common overall.[1][3]
What Do Real Patients Say About Headaches?
Patient forums and reviews on sites like Drugs.com report headaches in about 8-10% of Cosentyx users, often starting within the first few weeks of injections. Some describe them as tension-like or migraine-triggered, easing over time; others note they worsen with loading doses.[4]
Why Might Cosentyx Trigger Headaches?
The exact mechanism isn't fully clear, but IL-17 inhibition can alter immune responses, potentially affecting vascular or inflammatory pathways in the brain. Dehydration from gastrointestinal side effects or injection-site stress may contribute in some cases.[2][5]
How Long Do Headaches Last and When to Worry?
Most headaches appear early in treatment and subside within days to weeks as the body adjusts. Seek medical advice if they persist beyond 2 weeks, intensify, or include vision changes, nausea, or neck stiffness—these could signal rarer issues like aseptic meningitis reported in post-marketing data.[1][3]
Managing Headaches While on Cosentyx
Over-the-counter pain relievers like acetaminophen or ibuprofen help most users. Staying hydrated, avoiding triggers (e.g., stress, caffeine), and timing injections consistently reduce occurrences. Doctors may adjust dosing if headaches interfere with adherence.[2][4]
Compared to Other Biologics
Cosentyx's headache rate (10-12%) is similar to Humira (11%) and Stelara (9%), but lower than Tremfya (up to 15%). Placebo-adjusted rates are modest across biologics, suggesting immune modulation plays a role universally.[1][3]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: ClinicalTrials.gov - Secukinumab Studies (e.g., NCT01695239)
[4]: Drugs.com - Cosentyx User Reviews
[5]: Drugs.com - Cosentyx Side Effects